Following these transactions, the reporting entities retain a significant stake in NewAmsterdam Pharma, owning a total of 10,686,018 shares. Despite the sales, the Forbion entities remain major stakeholders in the company, with shares held indirectly through their joint investment vehicle, ForGrowth NAP BV. The transactions were part of a structured plan, and shares were sold in multiple transactions at prices within specified ranges. The reporting entities have committed to providing full details of the transactions upon request. For deeper insights into NAMS's valuation and comprehensive analysis, investors can access the full Pro Research report available at InvestingProcovering over 1,400 US stocks with expert analysis and actionable intelligence. For deeper insights into NAMS's valuation and comprehensive analysis, investors can access the full Pro Research report available at InvestingProcovering over 1,400 US stocks with expert analysis and actionable intelligence.
Following these transactions, the reporting entities retain a significant stake in NewAmsterdam Pharma, owning a total of 10,686,018 shares. Despite the sales, the Forbion entities remain major stakeholders in the company, with shares held indirectly through their joint investment vehicle, ForGrowth NAP BV. The transactions were part of a structured plan, and shares were sold in multiple transactions at prices within specified ranges. The reporting entities have committed to providing full details of the transactions upon request. For deeper insights into NAMS's valuation and comprehensive analysis, investors can access the full Pro Research report available at InvestingProcovering over 1,400 US stocks with expert analysis and actionable intelligence.
Following these transactions, the reporting entities retain a significant stake in NewAmsterdam Pharma, owning a total of 10,686,018 shares. Despite the sales, the Forbion entities remain major stakeholders in the company, with shares held indirectly through their joint investment vehicle, ForGrowth NAP BV.
The transactions were part of a structured plan, and shares were sold in multiple transactions at prices within specified ranges. The reporting entities have committed to providing full details of the transactions upon request.
In other recent news, NewAmsterdam Pharma Co NV has seen several key developments. The company's lead drug candidate obicetrapib has shown promising results in Phase 3 trials, leading H.C. Wainwright to: Scotiabank (TSX:) and Leerink Partners to issue positive reviews and increase their price targets. The drug showed a significant reduction in LDL-C cholesterol levels and major cardiovascular adverse events.
In addition, NewAmsterdam Pharma has suspended and terminated a previously filed automated teller machine (ATM) prospectus related to a $150 million stock sale plan. The company also restated its financial statements for the years ending 2022 and 2021 due to identified errors in calculating net loss per common share, and welcomed two new board members, Mark C. McKenna and Wouter Jiustra.
Looking ahead, New Amsterdam is preparing for the Phase 3 HORIZON trial of belacarsen in 2025 and readouts of the Phase 3 Broadway trial, expected in the fourth quarter of 2024. These are the latest developments for New Amsterdam Pharma.
This article was created with the power of artificial intelligence and reviewed by an editor. For more information, see our terms and conditions.
